{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:32:08Z","timestamp":1789662728746,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NS139383"],"award-info":[{"award-number":["RO1NS139383"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.tjpad.2025.100359","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:24:18Z","timestamp":1761528258000},"page":"100359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Add-on combination therapy with monoclonal antibodies: Implications for drug development"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0176-9184","authenticated-orcid":false,"given":"Aaron H","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tjpad.2025.100359_bib0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100359_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100359_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2024.100001","article-title":"Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation","volume":"12","author":"Cummings","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100359_bib0004","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100359_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"issue":"16","key":"10.1016\/j.tjpad.2025.100359_bib0006","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2019.4782","article-title":"Diagnosis and Management of Dementia: Review","volume":"322","author":"Arvanitakis","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100359_bib0007","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100359_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100359_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00570","article-title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","volume":"22","author":"Cummings","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100359_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms","volume":"21","author":"Greenberg","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100359_bib0011","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3233\/JAD-220120","article-title":"Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease","volume":"88","author":"Nabirotchkin","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100359_bib0012","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10928-023-09876-6","article-title":"Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases","volume":"51","author":"Geerts","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100359_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-025-00828-x","article-title":"Immune modulation to treat Alzheimer's disease","volume":"20","author":"Duggan","year":"2025","journal-title":"Mol Neurodegener"},{"issue":"s1","key":"10.1016\/j.tjpad.2025.100359_bib0014","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3233\/JAD-231126","article-title":"Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease","volume":"101","author":"Feldman","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"14","key":"10.1016\/j.tjpad.2025.100359_bib0015","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100359_bib0016","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.tjpad.2025.100359_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100359_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.inpsyc.2025.100108","article-title":"Globalization of Alzheimer's disease clinical trials: Current characteristics and future goals","author":"Cummings","year":"2025","journal-title":"Int Psychogeriatr"},{"issue":"9","key":"10.1016\/j.tjpad.2025.100359_bib0019","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","article-title":"A neuropsychological test battery for use in Alzheimer disease clinical trials","volume":"64","author":"Harrison","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.tjpad.2025.100359_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.dadm.2017.03.002","article-title":"Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire","volume":"8","author":"Jutten","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100359_bib0021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100359_bib0022","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab Clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100359_bib0023","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1002\/gps.4771","article-title":"Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: A systematically conducted narrative review","volume":"33","author":"Yang","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"10.1016\/j.tjpad.2025.100359_bib0024","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol"},{"issue":"21","key":"10.1016\/j.tjpad.2025.100359_bib0025","doi-asserted-by":"crossref","first-page":"e2065","DOI":"10.1212\/WNL.0000000000012853","article-title":"CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study","volume":"97","author":"Mila-Aloma","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.tjpad.2025.100359_bib0026","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial","volume":"76","author":"van Dyck","year":"2019","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2025.100359_bib0027","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/brain\/awab452","article-title":"A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment","volume":"145","author":"Levey","year":"2022","journal-title":"Brain"},{"issue":"19","key":"10.1016\/j.tjpad.2025.100359_bib0028","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","article-title":"Eligibility for anti-amyloid treatment in a population-based study of cognitive aging","volume":"101","author":"Pittock","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.tjpad.2025.100359_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124500","article-title":"Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors","volume":"10","author":"Leinonen","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100359_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100096","article-title":"Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus","volume":"12","author":"Perneczky","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100359_bib0031","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"31","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:56:56Z","timestamp":1785963416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2274580725003012"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100359","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Add-on combination therapy with monoclonal antibodies: Implications for drug development","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Alzheimer's Drug Discovery Foundation. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100359"}}